Browsing by Author "Kocaturk, I."

Now showing 1 - 3 of 3

Comparison of clinic and demographic characteristics in vestibular migraine and migraine only patients
(2024.01.01) Kocaturk, I.; Atalay, F.; Anbar, S.S.
Background & Objective: The relationship between vertigo and migraine has been known for a long time. Many migraine patients are accompanied by vertigo. The term vestibular migraine (VM) is a clinical entity defined recently. Treatments for migraine only (MO) and VM patients differ partially. Therefore, it is essential to distinguish between these two clinical conditions. This study aims to reveal the clinical and demographic differences between MO and VM and determine the factors that will help diagnose and manage VM. Method: A total of 80 patients, 40 diagnosed with MO according to ICHD-3 and 40 diagnosed with VM, who applied to the Neurology clinic of a tertiary hospital between January and July 2023, were included in this prospective study. The patients' ages, genders, education levels, medical and family history, migraine duration, migraine onset age, migraine attack frequency, and medication use were recorded. All patients completed a battery of questionnaires, including the World Health Organization Quality of Life-Bref (WHOQOL-BREF), Dizziness Handicap Inventory (DHI), Activities-Specific Balance Confidence Scale (ABCS), and Beck Depression Inventory (BDI). Results: Patients with VM experienced significantly more sleep disturbances, depressive symptoms, movement disorders, imbalance, menstruation-related headaches, and aura compared to those with migraine MO. In contrast, MO patients reported more throbbing headaches and a better response to analgesics. Conclusion: MO and VM patients have distinct clinical characteristics. Recognizing these basic differences has important clinical benefits, allowing for precise diagnosis and treatment of VM.
Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies
(2024.01.01) Kocaturk, I.; Gulten, S.; Ece, B.; Guven, F.M.K.
Neurogenic inflammation plays a significant role in the pathogenesis of migraines. This study aimed to investigate the serum levels of prostaglandin E2 (PGE2), lipoxin A4 (LXA4), and other inflammatory biomarkers (C-reactive protein, fibrinogen) in migraine patients. In total, 53 migraine patients and 53 healthy controls were evaluated. Blood serum samples were collected during both attack and interictal periods and compared with the control group. In both the attack and interictal periods, PGE2 and LXA4 values were significantly lower in migraine patients compared to the control group (p < 0.001). Additionally, PGE2 values during the attack period were significantly higher than those during the interictal period (p = 0.016). Patients experiencing migraine attacks lasting >= 12 h had significantly lower serum PGE2 and LXA4 levels compared to those with attacks lasting < 12 h (p = 0.028 and p = 0.009, respectively). In ROC analysis, cut-off values of 332.7 pg/mL for PGE2 and 27.2 ng/mL for LXA4 were determined with 70-80% sensitivity and specificity. In conclusion, PGE2 and LXA4 levels are significantly lower in migraine patients during both interictal and attack periods. Additionally, the levels of LXA4 and PGE2 decrease more with the prolongation of migraine attack duration. Our findings provide a basis for future treatment planning.
Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies
(2024) Kocaturk, I.; Gulten, S.; Ece, B.; Kukul Guven, F.M.
Neurogenic inflammation plays a significant role in the pathogenesis of migraines. This study aimed to investigate the serum levels of prostaglandin E2 (PGE2), lipoxin A4 (LXA4), and other inflammatory biomarkers (C-reactive protein, fibrinogen) in migraine patients. In total, 53 migraine patients and 53 healthy controls were evaluated. Blood serum samples were collected during both attack and interictal periods and compared with the control group. In both the attack and interictal periods, PGE2 and LXA4 values were significantly lower in migraine patients compared to the control group ( < 0.001). Additionally, PGE2 values during the attack period were significantly higher than those during the interictal period ( = 0.016). Patients experiencing migraine attacks lasting ≥ 12 h had significantly lower serum PGE2 and LXA4 levels compared to those with attacks lasting < 12 h ( = 0.028 and = 0.009, respectively). In ROC analysis, cut-off values of 332.7 pg/mL for PGE2 and 27.2 ng/mL for LXA4 were determined with 70-80% sensitivity and specificity. In conclusion, PGE2 and LXA4 levels are significantly lower in migraine patients during both interictal and attack periods. Additionally, the levels of LXA4 and PGE2 decrease more with the prolongation of migraine attack duration. Our findings provide a basis for future treatment planning.